Loading clinical trials...
Loading clinical trials...
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease
Conditions
Interventions
TRx0237 200 mg/day
Placebo
Locations
95
United States
Xenoscience, Inc / 21st Century Neurology
Phoenix, Arizona, United States
NoesisPharma Clinical Trials
Phoenix, Arizona, United States
CITrials
Bellflower, California, United States
ATP Clinical Research, Inc.
Costa Mesa, California, United States
Southern California Research, LLC
Fountain Valley, California, United States
Feldman, Robert MD
Laguna Hills, California, United States
Start Date
October 1, 2012
Primary Completion Date
May 1, 2016
Completion Date
May 1, 2016
Last Updated
March 14, 2018
NCT07033494
NCT06159673
NCT07457138
NCT07422857
NCT07214727
NCT06584357
Lead Sponsor
TauRx Therapeutics Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions